Compare · BBNX vs SYK
BBNX vs SYK
Side-by-side comparison of Beta Bionics Inc. (BBNX) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.69B, about 240.8x BBNX ($467.9M).
- Over the past year, BBNX is down 29.8% and SYK is down 23.1% - SYK leads by 6.7 points.
- SYK has been more active in the news (9 items in the past 4 weeks vs 4 for BBNX).
- SYK has more recent analyst coverage (25 ratings vs 16 for BBNX).
- Company
- Beta Bionics Inc.
- Stryker Corporation
- Price
- $10.49-0.80%
- $294.32+0.72%
- Market cap
- $467.9M
- $112.69B
- 1M return
- +7.04%
- -13.43%
- 1Y return
- -29.79%
- -23.07%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 4
- 9
- Recent ratings
- 16
- 25
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest BBNX
- Beta Bionics to Present at the Bank of America Securities Health Care Conference
- SEC Form 10-Q filed by Beta Bionics Inc.
- Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
- SEC Form DEFA14A filed by Beta Bionics Inc.
- SEC Form DEF 14A filed by Beta Bionics Inc.
- Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
- Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.
- Chief Medical Officer Russell Steven Jon sold $30,069 worth of shares (1,025 units at $29.34), decreasing direct ownership by 0.57% to 178,071 units (SEC Form 4)
Latest SYK
- Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
- Stryker declares an $0.88 per share quarterly dividend
- Stryker to participate in the Bank of America Securities 2026 Global Healthcare Conference
- Stryker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Stryker reports first quarter 2026 operating results
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Leerink Partners initiated coverage on Stryker with a new price target
- Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
- Amendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure